LAEKNA-B(02105),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02105 LAEKNA-B

Market Closed 09-04 16:08:03

7.190

+0.320

+4.66%

High7.495	Low7.020	Vol2.17M
Open7.020	D1 Closing6.870	Amplitude6.91%
Mkt Cap3.23B	Tradable Cap3.23B	Total Shares449.00M
T/O15.76M	T/O Rate0.48%	Tradable Shares449.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02105","market":"HK","secType":"STK","nameCN":"LAEKNA-B","latestPrice":7.19,"timestamp":1788509283005,"preClose":6.87,"halted":0,"volume":2171500,"delay":0,"changeRate":0.046579330422125226,"floatShares":449000000,"shares":449000000,"eps":-0.59,"marketStatus":"Market Closed","change":0.32,"latestTime":"09-04 16:08:03","open":7.02,"high":7.495,"low":7.02,"amount":15764885,"amplitude":0.069141,"askPrice":7.19,"askSize":2000,"bidPrice":7.185,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-0.262,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788744600000},"marketStatusCode":7,"adr":0,"listingDate":1687968000000,"exchange":"SEHK","adjPreClose":6.87,"openAndCloseTimeList":[[1788485400000,1788494400000],[1788498000000,1788508800000]],"volumeRatio":0.5613390698935034,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02105","defaultTab":"news","newsList":[{"id":"1121016709","title":"Laekna Maintains 449.33 Million Shares Outstanding in August 2026, Confirms Adequate Public Float","url":"https://stock-news.laohu8.com/highlight/detail?id=1121016709","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121016709?lang=en_us&edition=fundamental","pubTime":"2026-09-04 17:47","pubTimestamp":1788515267,"startTime":"0","endTime":"0","summary":"Laekna, Inc. (Laekna) reported no changes to its capital structure for the month ended 31 August 2026, according to the company’s monthly return filed with Hong Kong Exchanges and Clearing Limited on...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157665370","title":"HK Stocks in Focus: LAEKNA-B (02105) Jumps Over 9% in Early Trading After First Patient Dosed in Phase I Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1157665370","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157665370?lang=en_us&edition=fundamental","pubTime":"2026-09-01 09:52","pubTimestamp":1788227576,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) saw its share price surge more than 9% in early trading on Thursday, with the stock last changing hands at HK$7.005, marking a gain of 9.37%. Trading volume has reached approximately...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","KCAI","VXUS","02105","BK1161","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163609757","title":"LAEKNA-B Initiates First-Patient Dosing in Phase I Trial of LAE118, a Novel Pan-Mutant-Selective PI3Kα Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=1163609757","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163609757?lang=en_us&edition=fundamental","pubTime":"2026-09-01 08:22","pubTimestamp":1788222165,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) has announced that it has commenced subject recruitment for its Phase I clinical study of LAE118, designed to treat advanced solid tumors, in China. The company confirmed that...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664899538","title":"Laekna Enrolls First Patient in China Phase I Trial of Cancer Drug Candidate Lae118","url":"https://stock-news.laohu8.com/highlight/detail?id=2664899538","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664899538?lang=en_us&edition=fundamental","pubTime":"2026-09-01 08:11","pubTimestamp":1788221498,"startTime":"0","endTime":"0","summary":"Laekna enrolls first patient in China Phase I trial of cancer drug candidate LAE118Laekna began a Phase I study of LAE118 in China for advanced solid tumors, enrolling the first participant.No clinica","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL5vvH85:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662989032","title":"Analysts Just Made A Significant Upgrade To Their Laekna, Inc. (HKG:2105) Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=2662989032","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662989032?lang=en_us&edition=fundamental","pubTime":"2026-08-28 06:11","pubTimestamp":1787868676,"startTime":"0","endTime":"0","summary":"Laekna, Inc. ( HKG:2105 ) shareholders will have a reason to smile today, with the analysts making substantial upgrades...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2105/laekna-shares/news/analysts-just-made-a-significant-upgrade-to-their-laekna-inc","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2105/laekna-shares/news/analysts-just-made-a-significant-upgrade-to-their-laekna-inc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174075405","title":"LAEKNA-B Announces Interim Results with Other Income Climbing 30.41% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1174075405","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174075405?lang=en_us&edition=fundamental","pubTime":"2026-08-26 08:50","pubTimestamp":1787705422,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) has unveiled its interim results for the six-month period ending June 30, 2026, showcasing a robust increase in other income alongside a significant narrowing of its net loss.The...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180311859","title":"LAEKNA-B (02105) Posts Interim Results: Other Income Up 30.41% to RMB 25.962 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1180311859","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180311859?lang=en_us&edition=fundamental","pubTime":"2026-08-25 23:06","pubTimestamp":1787670381,"startTime":"0","endTime":"0","summary":"LAEKNA-B (02105) has disclosed its interim results for the six months ended June 30, 2026. The group recorded other income of RMB 25.962 million, representing a year-on-year increase of 30.41%....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662753968","title":"Laekna FY26 H1 Net Loss Narrows to RMB 2.55 Million; Revenue Rises to RMB 150.28 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662753968","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662753968?lang=en_us&edition=fundamental","pubTime":"2026-08-25 22:48","pubTimestamp":1787669292,"startTime":"0","endTime":"0","summary":"Laekna FY26 H1 net loss narrows to RMB 2.55 million; revenue rises to RMB 150.28 millionLaekna posted revenue of RMB 150.28 million, swinging from no revenue a year earlier, as it booked out-licensing","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nNDL9rwrF6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190930697","title":"Laekna forecasts up to RMB155.00 million H1 2026 revenue, trims net loss by 96%","url":"https://stock-news.laohu8.com/highlight/detail?id=1190930697","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190930697?lang=en_us&edition=fundamental","pubTime":"2026-08-17 08:05","pubTimestamp":1786925113,"startTime":"0","endTime":"0","summary":"Laekna, Inc. (Laekna) has issued a positive profit alert for the six months ended 30 June 2026, indicating a sharp turnaround in its interim financial performance. Revenue Surge   • Management...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660810305","title":"Laekna Expects H1 Net Loss no More than RMB 5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2660810305","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660810305?lang=en_us&edition=fundamental","pubTime":"2026-08-17 08:01","pubTimestamp":1786924900,"startTime":"0","endTime":"0","summary":"Laekna expects H1 net loss no more than RMB 5 millionLaekna guided for RMB 145 million to RMB 155 million revenue for the six months ended June 30, 2026, versus nil a year earlier.Net loss forecast at","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL6XmqGY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660103036","title":"Laekna - Expects Revenue of Rmb145 Mln-Rmb155 Mln for Six Months Ended June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2660103036","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660103036?lang=en_us&edition=fundamental","pubTime":"2026-08-17 08:01","pubTimestamp":1786924890,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nFWN44B2QB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111926246","title":"LAEKNA-B's LAE002 NDA Accepted by CDE, Signaling a Domestic AKT Inhibitor Major Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=1111926246","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111926246?lang=en_us&edition=fundamental","pubTime":"2026-08-13 08:50","pubTimestamp":1786582251,"startTime":"0","endTime":"0","summary":"AstraZeneca's Q2 2026 financial report highlighted the oncology asset Truqap, an AKT inhibitor, as a standout performer. Initially undervalued upon launch (Evaluate Pharma projected a peak of $690...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1223083913.SGD","XME","LU1223082519.USD","SIL","02105","BK1161","LU1223082196.USD","SGDM","GDXJ","BK4017","CDE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658926565","title":"Laekna Breast Cancer Drug NDA Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2658926565","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658926565?lang=en_us&edition=fundamental","pubTime":"2026-08-12 13:43","pubTimestamp":1786513430,"startTime":"0","endTime":"0","summary":"Laekna  said China's National Medical Products Administration accepted the new drug application for afuresertib  to treat certain patients with advanced breast cancer.The application is supported by positive results from the company's Phase III AFFIRM-205 clinical trial, according to a Wednesday Hong Kong bourse filing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658294285","title":"New Drug Application for Lae002 (Afuresertib) Accepted by China's National Medical Products Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2658294285","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658294285?lang=en_us&edition=fundamental","pubTime":"2026-08-12 08:45","pubTimestamp":1786495500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA92YK0S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133141778","title":"Laekna gains NMPA nod to review NDA for AKT inhibitor Afuresertib in HR+/HER2- breast cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1133141778","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133141778?lang=en_us&edition=fundamental","pubTime":"2026-08-12 08:23","pubTimestamp":1786494226,"startTime":"0","endTime":"0","summary":"Laekna, Inc. (Laekna; HKEX: 02105) announced that China’s Center for Drug Evaluation of the National Medical Products Administration has accepted the New Drug Application for LAE002 (afuresertib) as...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658944315","title":"Laekna Says China Regulator Accepts NDA for Afuresertib in Hr+/her2- Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2658944315","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658944315?lang=en_us&edition=fundamental","pubTime":"2026-08-12 08:19","pubTimestamp":1786493987,"startTime":"0","endTime":"0","summary":"Laekna says China regulator accepts NDA for afuresertib in HR+/HER2- breast cancerChina’s NMPA accepted Laekna’s NDA for LAE002 (afuresertib) in HR+/HER2- advanced breast cancer with PIK3CA/AKT1/PTEN ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL4mhzQV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658944393","title":"Laekna - Nda for Lae002 (Afuresertib) Accepted by China's Nmpa for Hr+/Her2- Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2658944393","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658944393?lang=en_us&edition=fundamental","pubTime":"2026-08-12 08:18","pubTimestamp":1786493888,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4481DO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145289408","title":"Laekna Sets 25 Aug 2026 Board Meeting to Review 1H 2026 Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1145289408","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145289408?lang=en_us&edition=fundamental","pubTime":"2026-08-07 17:25","pubTimestamp":1786094753,"startTime":"0","endTime":"0","summary":"Laekna, Inc. has scheduled a board meeting for 25 August 2026 to consider and approve the interim financial results for the six months ended 30 June 2026 and to authorize their publication. The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657193306","title":"Laekna Sets Board Meeting to Review Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657193306","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657193306?lang=en_us&edition=fundamental","pubTime":"2026-08-07 17:06","pubTimestamp":1786093564,"startTime":"0","endTime":"0","summary":"Laekna sets board meeting to review interim resultsLaekna will hold a board meeting on Aug. 25, 2026 to review interim results for the six months ended June 30, 2026.Disclaimer:This news brief was cre","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL2kYHjj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124883745","title":"LAEKNA-B buys back 39,000 shares on 15 July; cumulative repurchase climbs to 219,000 shares, or 0.05% of share base","url":"https://stock-news.laohu8.com/highlight/detail?id=1124883745","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124883745?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:00","pubTimestamp":1784113259,"startTime":"0","endTime":"0","summary":"Laekna-B (Laekna, Inc.) disclosed a Next Day Disclosure Return on 15 July 2026, detailing the latest progress of its on-market share repurchase programme approved on 5 June 2026. Key takeaways •...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.laekna.com","stockEarnings":[{"period":"1week","weight":0.1963},{"period":"1month","weight":0.0902},{"period":"3month","weight":-0.2781},{"period":"6month","weight":-0.4478},{"period":"1year","weight":-0.5412},{"period":"ytd","weight":-0.4702}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0276},{"period":"6month","weight":-0.0041},{"period":"1year","weight":0.0236},{"period":"ytd","weight":0.0008}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer, liver diseases and obesity. The Company is still in the research and development stage. The Company's pipeline products include Afuresertib (LAE002), LAE001, LAE109, LAE111, LAE112, LAE113, LAE117, LAE118, LAE119, LAE102, LAE103, LAE104, LAE105, LAE106, LAE120, LAE123, and others. The Afuresertib is an adenosine triphosphate (ATP) competitive AKT inhibitor. The LAE001 is an androgen synthesis inhibitor that can inhibit CYP17A1 and CYP11B2 at the same time. The Company mainly conducts business in the Chinese, America, European, Korean, and other markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.264392},{"month":2,"riseRate":0.666667,"avgChangeRate":0.234103},{"month":3,"riseRate":0.666667,"avgChangeRate":0.090739},{"month":4,"riseRate":0.333333,"avgChangeRate":0.001974},{"month":5,"riseRate":0.666667,"avgChangeRate":0.062052},{"month":6,"riseRate":0,"avgChangeRate":-0.226423},{"month":7,"riseRate":0.25,"avgChangeRate":-0.072516},{"month":8,"riseRate":0.75,"avgChangeRate":0.06659},{"month":9,"riseRate":0.75,"avgChangeRate":0.06103},{"month":10,"riseRate":0.666667,"avgChangeRate":0.10793},{"month":11,"riseRate":1,"avgChangeRate":0.401946},{"month":12,"riseRate":0,"avgChangeRate":-0.176326}],"exchange":"SEHK","name":"LAEKNA-B","nameEN":"LAEKNA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LAEKNA-B(02105),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LAEKNA-B(02105) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LAEKNA-B,02105,LAEKNA-B股票,LAEKNA-B股票老虎,LAEKNA-B股票老虎国际,LAEKNA-B行情,LAEKNA-B股票行情,LAEKNA-B股价,LAEKNA-B股市,LAEKNA-B股票价格,LAEKNA-B股票交易,LAEKNA-B股票购买,LAEKNA-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LAEKNA-B(02105),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LAEKNA-B(02105) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}